Envestnet Asset Management Inc Sage Therapeutics, Inc. Transaction History

Envestnet Asset Management Inc

$302 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$40.65 - $59.54 $39,186 - $57,396	964 Added 7.93%	13,118 $616,000
Q1 2023 May 11, 2023	BUY	$37.27 - $46.57 $42,972 - $53,695	1,153 Added 10.48%	12,154 $509,000
Q4 2022 Feb 07, 2023	BUY	$32.2 - $43.61 $15,713 - $21,281	488 Added 4.64%	11,001 $419,000
Q3 2022 Nov 10, 2022	BUY	$32.28 - $43.27 $7,811 - $10,471	242 Added 2.36%	10,513 $412,000
Q2 2022 Aug 03, 2022	SELL	$27.52 - $37.99 $34,152 - $47,145	-1,241 Reduced 10.78%	10,271 $332,000
Q1 2022 May 04, 2022	SELL	$30.71 - $45.71 $351,199 - $522,739	-11,436 Reduced 49.83%	11,512 $381,000
Q4 2021 Feb 04, 2022	BUY	$37.06 - $47.11 $420,927 - $535,075	11,358 Added 98.0%	22,948 $976,000
Q3 2021 Oct 07, 2021	SELL	$40.26 - $57.37 $57,128 - $81,408	-1,419 Reduced 10.91%	11,590 $514,000
Q2 2021 Aug 04, 2021	BUY	$54.88 - $79.29 $241,197 - $348,479	4,395 Added 51.02%	13,009 $739,000
Q1 2021 May 04, 2021	BUY	$70.65 - $96.76 $361,445 - $495,024	5,116 Added 146.26%	8,614 $645,000
Q4 2020 Feb 02, 2021	BUY	$58.41 - $89.06 $204,318 - $311,531	3,498 New	3,498 $303,000
Q1 2020 Apr 23, 2020	SELL	$26.15 - $77.24 $162,862 - $481,050	-6,228 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$60.18 - $154.77 $372,213 - $957,252	-6,185 Reduced 49.83%	6,228 $450,000
Q3 2019 Oct 17, 2019	BUY	$140.29 - $189.96 $133,836 - $181,221	954 Added 8.33%	12,413 $1.74 Million
Q2 2019 Aug 02, 2019	BUY	$157.85 - $183.09 $337,009 - $390,897	2,135 Added 22.9%	11,459 $2.1 Million
Q1 2019 May 10, 2019	BUY	$89.33 - $163.65 $163,920 - $300,297	1,835 Added 24.5%	9,324 $1.48 Million
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $613,648 - $1.05 Million	7,489 New	7,489 $717,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $855,867 - $1.05 Million	-6,197 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$140.36 - $175.76 $521,297 - $652,772	3,714 Added 149.58%	6,197 $970,000
Q1 2018 May 09, 2018	SELL	$152.15 - $192.33 $21,453 - $27,118	-141 Reduced 5.37%	2,483 $400,000
Q4 2017 Feb 20, 2018	SELL	$60.72 - $167.34 $17,123 - $47,189	-282 Reduced 9.7%	2,624 $432,000
Q3 2017 Nov 13, 2017	BUY	$61.4 - $88.52 $73,925 - $106,578	1,204 Added 70.74%	2,906 $182,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,702	1,702 $136,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account